SS-31 (Elamipretide): What the Evidence Actually Shows

Grade B in trialsInvestigational

The short version

A tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin.
Developed by Stealth BioTherapeutics with real Phase 2 and Phase 3 programmes.
Studied in primary mitochondrial myopathy, Barth syndrome and dry age-related macular degeneration.
Not approved. Results across the programme have been mixed.
Sold on the gray market as a longevity compound, which is not what the trials studied.

What it is

Elamipretide is unusual in this category because it has a specific, well-described molecular target. It accumulates in the inner mitochondrial membrane and interacts with cardiolipin, a phospholipid essential to the structure of the electron transport chain. Damaged cardiolipin impairs energy production, and the hypothesis is that stabilising it restores function.

What the research shows

This has been tested properly, which is rare here. Trials in primary mitochondrial myopathy produced mixed results, with some endpoints met and others not. Work in Barth syndrome, an ultra-rare genetic condition, has been more encouraging. Ophthalmic work in dry AMD has also been pursued.

What has not been studied is the use it is actually marketed for on the gray market: healthy adults taking it for energy, longevity or performance. There is no trial population resembling that.

The gap worth naming

Trials in people with genetic mitochondrial disease tell you about people with genetic mitochondrial disease. Extrapolating from a rare disease population to healthy adults is the most common evidence error in this whole category, and SS-31 is a textbook case of it.

What this will not do

It will not have been tested in anyone like you unless you have a diagnosed mitochondrial disorder.
It will not be legally available. It is an investigational drug.

Full library · Safety and sourcing · Reconstitution calculator · The 2026 regulatory picture